Search
Flupirtine
go.drugbank.com/drugs/DB06623InvestigationalFlupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. … It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
Lovotibeglogene autotemcel
go.drugbank.com/drugs/DB18680ApprovedInvestigational[L49266] It was approved alongside [exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who
Fosfructose
go.drugbank.com/drugs/DB13863InvestigationalCategories: Compounds used in a research, industrial, or household settingGlyphosate
go.drugbank.com/drugs/DB04539ExperimentalCategories: Compounds used in a research, industrial, or household setting, N-substituted GlycinesRhodamine 6G
go.drugbank.com/drugs/DB03825InvestigationalCategories: Compounds used in a research, industrial, or household settingHGTV-43
go.drugbank.com/drugs/DB05807ExperimentalHGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc. … HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection.
PDPSC18
go.drugbank.com/drugs/DB05167ExperimentalPDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.
ISIS 14803
go.drugbank.com/drugs/DB05803Investigationalprotein expression in cell culture. … ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits
Rocaglamide
go.drugbank.com/drugs/DB15495Experimental[A186796] Reports of _Aglaia_ anti-tumor activity date back as far as 1973, and rocaglamide-A was first isolated in 1982 from the species _A. elliptifolia_. … [didesmethylrocaglamide]) are currently being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and carcinomas, as well as adjuvant therapy in the treatment of